Key clinical point: A real-world study has revealed factors associated with longer overall survival in patients who receive cabozantinib to treat heavily pretreated, metastatic renal cell carcinoma.

Major finding: Receiving cabozantinib at a starting dose of 60 mg/day (P = .0486), prior nephrectomy (P = .0109), favorable or intermediate risk according to the International Metastatic RCC Database Consortium (P < .0001), and body mass index of 25 kg/m2 or higher (P = .0021) were all significantly associated with better overall survival.

Study details: A retrospective analysis of 410 patients with metastatic renal cell carcinoma treated with cabozantinib.

Disclosures: The study was sponsored by Ipsen. Authors disclosed financial relationships with Amgen, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Exelixis, Ipsen, and numerous other companies.